All News
#OP0146 explores #US biomarkers in #at-risk RA individuals:
Tenosynovitis shows a HR of 2.9 to predict arthritis development - 57% of those with tenosynovitis developed arthritis vs 23% without
#EULAR2021 @RheumNow https://t.co/SPkzQqQ0e5
Paul Studenic Stiddyo ( View Tweet)
#OP0117 explores differences of TNFi or non-TNFi use on disease activity in a diverse population of the RISE register:
Black and Asian #RA patients greater reduction of #CDAI in non-TNFi
#EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#OP0127 A post-hoc analysis of two RCTs showed that continued
methotrexate increases clinical response rates in patients randomized to
placebo therapy who were considered as having previous insufficient response
to #bDMARDs. #EULAR2021 @RheumNow https://t.co/YeEVe0uwQs
Paul Studenic Stiddyo ( View Tweet)
Wednesday afternoon = @eular_org recommendations. @alessia_alunno presented EULAR PtC on COVID-19 pathophysiology and immunomodulatory therapies from the Rheumatology Perspective
Bottom Line: Proven efficacy in severe COVID-19 based on RCTs only dexamethason #EULAR2021 @RheumNow https://t.co/didtYEEWmq
Paul Studenic Stiddyo ( View Tweet)
Looking forward to the discussions in these sessions. #EULAR2021 https://t.co/GPLf4LbXLP
Paul Studenic Stiddyo ( View Tweet)
#OP0210
Analyses of RA patients using SRQ, DANBIO and national maternal registers: extensive anti-rheumatic treatment before and maternal disease activity during pregnancy associated with higher risk of pre term birth and small gestational age
#EULAR2021 @RheumNow https://t.co/qEniF4RC0l
Paul Studenic Stiddyo ( View Tweet)
#OP0229 GRAPPA recommendations crisply presented by @DrLauraCoates
Importantly it needs to be tailored to the patient taking amongst under comorbidities and the heterogeneity of features of the clinical presentation into account.
#EULAR2021 @RheumNow https://t.co/MpZGzhq0Ic
Paul Studenic Stiddyo ( View Tweet)
#OP0231 BADBIR register (incl. Ustekinumab & csDMARD treated patients) 2697 PsO without PsA & 590 PsO with PsA:
obesity, diabetes, hypetension and inabililty to work was more likely in Pso patients with PsA than patients with PsO alone
#EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#OP0233 In SELECT-PsA1 & 2 analyses for PsA with axial involvement: 31% / 34% of the studies population:
> Improvement of axial symptoms on upadacitinib across several outcomes compared to PLC!
> 1new onset of uveitis on upadacitinib
#EULAR2021
@RheumNow https://t.co/9YK1OYEorq
Paul Studenic Stiddyo ( View Tweet)
Dr. Gladman highlighted the full spectrum of #PsA in today's #EULAR2021 afternoon session.
"-> All domains need to be assessed in our psa patients!
-> Its interesting that we have not been able to identify genetic dispositions to particular features "
@RheumNow
Paul Studenic Stiddyo ( View Tweet)
Does clinical response equate good #HRQoL in #SLE? Dr Gomez analysed responders in #belimumab trials and showed up to 29% pts reported poor SF-36 (esp physical aspects). Physical functioning & fatigue improved with therapy #EULAR2021 #POS0101 @RheumNow https://t.co/IU1k0UetEx
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Is there a need to routinely monitor #ANA in patients treated on #TNF inhibitors? The jury👨⚖️is still out. Of N=211, Dr Oliveira reported 75.4% had seroconversion at median 31mths of TNFi therapy. Only 2/211 (0.9%) developed SLE (mild symptoms) #EULAR2021 #POS0204 @RheumNow https://t.co/UrFucJ9xnJ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#MachineLearning to unravel pathways associated with #SLE. Dr Morand analysed N=1760 pts from RCTs. Using deep learning algorithms, they identified novel pathways (CD4 Tcell Differentiation, Macrophage and DCs) in addition to known #IFN and #JAKSTAT #EULAR2021 #POS0351 @RheumNow https://t.co/Gc7zL8JQZe
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#Interferon as biomarkers in #RMD? Dr Burska on behalf of #EULAR TF reported heterogeneity in published papers re:IFN-I pathway activation assays, hence unable to perform meta-analyses of results.They proposed Consensus Terminology for IFN #research #EULAR2021 #POS0370 @RheumNow https://t.co/lbqy2xbEyt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In a UK study of newly diagnosed #SLE (within 12 months of meeting ACR criteria), Dr Yee reported BILAG-2004 Grade A or B was predictive of damage in the median FU of 73 months. MMF use appeared to be protective #EULAR2021 #POS0705 @RheumNow https://t.co/VROqTTrzwY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Is efficacy of #voclosporin in #lupus nephritis sustained at 2 years? N=116 pts on VOC and N=100 pts on Placebo enrolled in Extension Study. Dr Saxena reported patients on VOC continued meaningful ⬇️in uPCR and stable eGFR up to 2yrs vs Placebo #EULAR2021 #POS0681 @RheumNow https://t.co/M5MX7tW2CA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Still time to sign up for a place in today’s #lupus interest group at #EULAR2021 (last few spaces remaining)
🕒12:30 CEST / 11:30 UK
🧬 "Lupus, the next 10 years" 🔬where we will be joined by @edvital
📍Click EULAR Networking then Interest Group Discussion to join @EMEUNET https://t.co/6r7RYOi8VG
Chris Wincup chriswincup ( View Tweet)
Once approved, in what type of patients with #psoriaticarthritis would you treat with IL23-inhibitors? #EULAR2021 #OP0228 #OP0230 @RheumNow 🤔
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#Lupus Interest Group Meeting #EULAR2021. Working towards personalised medicine to improve treatment of our patients with lupus. Future of #SLE research are in good hands 👌#NEXTGEN @edvital @GeorgeARobinson @pekor002 @dalilatm Matteo Boemi, Teona @eular_org https://t.co/eK4oiwlJZO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Utility of salivary gland biopsy in #Sjogren?Dr Chatzis analysed biopsy from N=618 with =>1 yr FU before 🔼lymphoma. 58/618 developed lymphoma. Predictors identified were⬆️Focus Score, cryoglobulin & parotid swelling. FS=>4 predicted earlier lymphoma #EULAR2021 #OP0291 @RheumNow https://t.co/yFFZpBRvji
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
